Literature DB >> 16716612

A modified technique of delayed basilic transposition - initial results.

A Kapala1, J Szmytkowski, W Stankiewicz, S Dabrowiecki.   

Abstract

The radiocephalic wrist fistula remains the "gold standard" for primary vascular access placement according to NKF -DOQI guidelines. However, liberal inclusion criteria for dialysis therapy, as well as increasing longevity and prevalence of diabetes, have led to an increased number of patients with distal vessels unsuitable for vascular access creation. Another available location, and one used with increasing frequency, is the anterior cubital fossa. Arteriovenous anastomoses in this location leads to the development of two possible vascular accesses: cephalic and basilic. The basilic vein needs to be transposed to the anterior aspect of the arm. However, this procedure is technically difficult and carries a high risk of complications, often associated with axial torsion or kinking of the transposed vein during placement in the subcutaneous tunnel. The authors propose a simple technical modification which minimizes the risk of these complications. The main advantage is the prevention of axial torsion and kinking, as well as avoiding venous stenosis by transecting the vein at its widest point.

Entities:  

Mesh:

Year:  2006        PMID: 16716612     DOI: 10.1016/j.ejvs.2006.03.011

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  2 in total

1.  Randomized controlled trial comparing primary and staged basilic vein transposition.

Authors:  Stavros K Kakkos; Ioannis A Tsolakis; Spyros I Papadoulas; George C Lampropoulos; Evangelos E Papachristou; Nikolaos C Christeas; Dimitrios Goumenos; Miltos K Lazarides
Journal:  Front Surg       Date:  2015-04-29

2.  Comparison of one- and two-stage basilic vein transposition for arterio-venous fistula formation in haemodialysis patients: preliminary results.

Authors:  Sedat Ozcan; Ali Kemal Gür; Ali Umit Yener; Dolunay Odabaşi
Journal:  Cardiovasc J Afr       Date:  2013 Oct-Nov       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.